How PhRMA finally lost: the inside story of the group’s biggest lobbying failure in years

WASHINGTON —The drug industry’s storied lobbying group isn’t accustomed to bad news — and with its small army of well-connected advocates, it’s even less familiar with surprises.

For PhRMA, the news last winter was both.